Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma

Bookmark and Share
Published: 10 Dec 2019
Views: 598
Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Prof Peter Voorhees talks to ecancer at ASH 2019 in Orlando.

The data he presented demonstrate that adding daratumamab to RVd significantly improves response rates and depth of response, including sCR and MRD negativity.

As seen in other randomised studies, continued use of daratumumab improved depth of response.

The overall safety profile of D-RVd is consistent with previous reports with DARA plus SoC.

Likewise, similar to what was reported from CASSIOPEIA, stem cell mobilisation and ASCT are feasible with D-RVd, without a significant effect on haematopoietic reconstitution. The study is ongoing, with patients continuing maintenance therapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.